Literature DB >> 27714698

Acceptability of Mini-Tablets in Young Children: Results from Three Prospective Cross-over Studies.

Viviane Klingmann1.   

Abstract

To ensure optimal, reliable treatment, it is necessary to investigate the efficacy, safety and the optimal dose of drug substances and to develop suitable age-specific pharmaceutical formulations for the different paediatric age groups due to a lack of evidence-based therapeutic options for children. While WHO recommends the use of solid dosage forms in general, European Medicines Agency (EMA) requires evidence for the suitability of these dosage forms in the targeted age group. This review aims to summarize and discuss the data obtained in acceptability studies on the suitability of coated and uncoated mini-tablets in children of different ages in comparison to a sweet syrup considered as gold standard. The predefined outcome parameters 'acceptability' and 'capability to swallow' of the two different mini-tablet formulations (uncoated and film-coated) were statistically significantly higher than that of the syrup.

Entities:  

Keywords:  acceptability; drug administration; mini-tablets; paediatric drug dosage forms; swallowability

Mesh:

Substances:

Year:  2016        PMID: 27714698     DOI: 10.1208/s12249-016-0639-3

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  2 in total

1.  A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric Population.

Authors:  Manfred Wargenau; Sibylle Reidemeister; Ingrid Klingmann; Viviane Klingmann
Journal:  Ther Innov Regul Sci       Date:  2022-04-26       Impact factor: 1.337

Review 2.  Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence.

Authors:  Enrica Menditto; Valentina Orlando; Giuseppe De Rosa; Paola Minghetti; Umberto Maria Musazzi; Caitriona Cahir; Marta Kurczewska-Michalak; Przemysław Kardas; Elísio Costa; José Manuel Sousa Lobo; Isabel F Almeida
Journal:  Pharmaceutics       Date:  2020-01-03       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.